Marta Sanchez-Carbayo

Summary

Country: Spain

Publications

  1. ncbi request reprint Recent advances in bladder cancer diagnostics
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Biochem 37:562-71. 2004
  2. pmc Profiling bladder cancer using targeted antibody arrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Am J Pathol 168:93-103. 2006
  3. ncbi request reprint Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology and Computational Biology Center Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:778-89. 2006
  4. pmc Gene discovery in bladder cancer progression using cDNA microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 163:505-16. 2003
  5. ncbi request reprint Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6973-80. 2002
  6. pmc Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 162:609-17. 2003
  7. pmc A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells
    Angela Y Jia
    Department of Pathology and Cell Biology, Columbia University, New York, New York, USA
    Am J Pathol 182:1171-9. 2013
  8. ncbi request reprint Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Clin Chem 49:2096-100. 2003
  9. ncbi request reprint A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
  10. pmc Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Am J Pathol 171:1650-8. 2007

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Recent advances in bladder cancer diagnostics
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Biochem 37:562-71. 2004
    ..This review summarizes the reports utilizing high-throughput microarrays in bladder cancer and the implications of these analyses in the diagnosis and clinical management of patients with bladder cancer...
  2. pmc Profiling bladder cancer using targeted antibody arrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Am J Pathol 168:93-103. 2006
    ....
  3. ncbi request reprint Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology and Computational Biology Center Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:778-89. 2006
    ..Bladder cancer is a common malignancy characterized by a poor clinical outcome when tumors progress into invasive disease. We sought to define genetic signatures characteristic of aggressive clinical behavior in advanced bladder tumors...
  4. pmc Gene discovery in bladder cancer progression using cDNA microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 163:505-16. 2003
    ..The present study has identified molecular biomarkers of potential clinical significance and critical molecular targets associated with bladder cancer progression...
  5. ncbi request reprint Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6973-80. 2002
    ..However, it appears that deregulation of cell adhesion is a common event associated with tumor progression in uroepithelial neoplasms...
  6. pmc Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 162:609-17. 2003
    ..A potential tumor suppressor role in bladder cancer was revealed for KiSS-1. Moreover, it showed predictive value by identifying patients with poor outcome...
  7. pmc A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells
    Angela Y Jia
    Department of Pathology and Cell Biology, Columbia University, New York, New York, USA
    Am J Pathol 182:1171-9. 2013
    ..Notably, this study provides evidence of the possible origin relationship between CIS and normal umbrella cells...
  8. ncbi request reprint Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Clin Chem 49:2096-100. 2003
  9. ncbi request reprint A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
    ..In this study, we aim to evaluate the SNP309 in bladder cancer and to link it to TP53 status...
  10. pmc Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Am J Pathol 171:1650-8. 2007
    ..This study further reveals that TP53 mutations are frequent events in bladder cancer progression and identified gelsolin related to TP53 status, tumor staging, and clinical outcome by independent high-throughput strategies...
  11. ncbi request reprint Molecular alterations associated with bladder cancer progression
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain
    Semin Oncol 34:75-84. 2007
    ..Integration of data generated from in-depth clinical evaluation, histologic tumor characteristics, and validated biomarkers could provide highly accurate, predictive tools for management of the bladder cancer patient...
  12. ncbi request reprint Antibody arrays: technical considerations and clinical applications in cancer
    Marta Sanchez-Carbayo
    Tumor Markers Group, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Chem 52:1651-9. 2006
    ..Furthermore, identification and validation of protein expression patterns, characteristic of cancer progression, and tumor subtypes may intervene and improve tailored therapies in the clinical management of cancer patients...
  13. pmc Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression
    Orit Karni-Schmidt
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
    Am J Pathol 178:1350-60. 2011
    ..This study highlights the relevance of p63 isoforms in both urothelial development and bladder carcinoma progression, with ΔNp63 acting as an oncogene in certain invasive bladder tumors...
  14. ncbi request reprint Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Clin Chem 49:23-31. 2003
    ..High-throughput microarrays represent novel means for cancer research and tumor marker discovery...
  15. ncbi request reprint Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes
    Marta Sanchez-Carbayo
    Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, York, New York 10021, USA
    Lab Invest 83:507-17. 2003
    ..This study further elucidates the genetic events associated with MDR1 expression and identifies novel targets associated with multidrug resistance...
  16. ncbi request reprint Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Oncogene 22:5298-305. 2003
    ..Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer...
  17. pmc Differential exoprotease activities confer tumor-specific serum peptidome patterns
    Josep Villanueva
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 116:271-84. 2006
    ..Our findings also have important implications for future peptide biomarker discovery efforts...
  18. ncbi request reprint Molecular profiling of tumor progression in head and neck cancer
    Thomas J Belbin
    Department of Pathology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY 10461, USA
    Arch Otolaryngol Head Neck Surg 131:10-8. 2005
    ..To assess gene expression changes associated with tumor progression in patients with squamous cell carcinoma of the oral cavity...
  19. ncbi request reprint Dissecting cancer serum protein profiles using antibody arrays
    Marta Sanchez-Carbayo
    Tumor Markers Group, Spanish National Cancer Center CN10, Madrid, Spain
    Methods Mol Biol 428:263-87. 2008
    ..Technical requirements such as lower sample volume, antibody concentration, format versatility, and high reproducibility support their increasing impact in cancer research...
  20. ncbi request reprint Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:919-26; discussion 926. 2006
    ..We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort...
  21. ncbi request reprint Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 173:1518-25. 2005
    ..We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort...
  22. doi request reprint Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
    Georg C Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 101:561-5. 2008
    ..To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC)...
  23. ncbi request reprint Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder
    Pierre I Karakiewicz
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    BJU Int 97:997-1001. 2006
    ....